-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QN2JYkxTFeVFCtaVkYoEwni17BypZlK75Vq0EKN5EliRKHoAC1tSfPEYFO5ZIBK6 8O5PfBD6df2ff+Sk8WXCrQ== 0001144204-11-008502.txt : 20110214 0001144204-11-008502.hdr.sgml : 20110214 20110214174705 ACCESSION NUMBER: 0001144204-11-008502 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101231 FILED AS OF DATE: 20110214 DATE AS OF CHANGE: 20110214 EFFECTIVENESS DATE: 20110214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 11608483 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v210979_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2010 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 21st Floor -------------------------------------------- New York, NY 10065-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-339-5633 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. February 11, 2011 - -------------------------- --------------------------- -------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 65 ----------- Form 13F Information Table Entry Value: $2,293,648 ----------- (thousands) List of Other Included Managers: None Baker Brothers Form 13F 9-30-2010
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY Name of Issuer CUSIP (x1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ---------------------------- ------- ------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 211 175,588 SH SOLE 175,588 Achillion COM 00448Q201 6,112 1,472,697 SH SOLE 1,472,697 Acorda Therapeutics COM 00484M106 13,847 507,975 SH SOLE 507,975 Adolor Corp. COM 00724X102 8,406 6,947,343 SH SOLE 6,947,343 Alere Inc. COM 01449J105 69,601 1,901,678 SH SOLE 1,901,678 Alere Inc. PFD Conv PFD CONV 01449J204 183 732 SH SOLE 732 Alsius Corp. COM 021211107 - 62,872 SH SOLE 62,872 Amicus Therapeutics COM 03152W109 5,519 1,174,191 SH SOLE 1,174,191 Amylin Pharmaceuticals COM 032346108 1,114 75,739 SH SOLE 75,739 Anacor Pharmaceuticals COM 032420101 6,444 1,200,000 SH SOLE 1,200,000 Anadys Pharmaceuticals Inc. COM 03252Q408 343 241,302 SH SOLE 241,302 Anthera Pharmaceuticals COM 03674U102 3,904 800,000 SH SOLE 800,000 AP Pharma COM 00202J203 3,097 6,861,818 SH SOLE 6,861,818 Aradigm Corp. COM 038505301 17 100,000 SH SOLE 100,000 Ardea Biosciences Inc. COM 03969P107 146,811 5,646,589 SH SOLE 5,646,589 Autoimmune Inc. COM 052776101 7 13,050 SH SOLE 13,050 Auxilium COM 05334D107 125,784 5,961,306 SH SOLE 5,961,306 Avanir Pharmaceuticals COM 05348P401 2,040 500,000 SH SOLE 500,000 Biocryst Pharmaceuticals Inc. COM 09058V103 28,764 5,563,615 SH SOLE 5,563,615 Biomarin COM 09061G101 13,587 504,518 SH SOLE 504,518 Bristol Myers COM 110122108 1,059 40,000 SH SOLE 40,000 Cadence Pharmaceuticals COM 12738T100 292 38,717 SH SOLE 38,717 Chelsea Therapeutics COM 163428105 7,235 964,700 SH SOLE 964,700 Cornerstone BioPharma COM 22674T105 650 112,337 SH SOLE 112,337 Cyclacel Pharmaceuticals Pfd. Conv. Ex 6% PFD CONV EX 23254L207 85 22,355 SH SOLE 22,355 Cumberland Pharmaceuticals COM 230770109 577 96,381 SH SOLE 96,381 Cypress Biosciences Inc. COM 232674507 1,944 300,000 SH SOLE 300,000 Dendreon Corp. COM 24823Q107 17,683 506,390 SH SOLE 506,390 Depomed COM 249908104 1,165 183,145 SH SOLE 183,145 Exelixis Inc. COM 30161Q104 4,105 500,000 SH SOLE 500,000 Genomic Health Inc. COM 37244C101 143,552 6,711,184 SH SOLE 6,711,184 GTX Inc. COM 40052B108 4,592 1,732,660 SH SOLE 1,732,660 Halozyme Therapeutics Inc. COM 40637H109 31,257 3,946,559 SH SOLE 3,946,559 Idera Pharmaceuticals Inc. COM 45168K108 833 288,401 SH SOLE 288,401 Incyte Corp. COM 45337C102 183,494 11,080,561 SH SOLE 11,080,561 Infinity Pharmaceuticals Inc. COM 45665G303 1,179 198,822 SH SOLE 198,822 Inhibitex Inc. COM 45719T103 2,268 872,303 SH SOLE 872,303 Inspire COM 457733103 16,800 2,000,000 SH SOLE 2,000,000 Intermune Inc. COM 45884X103 9,077 249,370 SH SOLE 249,370 Lexicon Pharmaceuticals COM 528872104 1,080 750,000 SH SOLE 750,000 Ligand Pharmaceuticals Inc. CLASS B 53220K207 746 83,613 SH SOLE 83,613 Medivation Inc. COM 58501N101 7,585 500,000 SH SOLE 500,000 Micromet COM 59509C105 20,579 2,534,311 SH SOLE 2,534,311 Pharmacyclics Inc. COM 716933106 12,221 2,010,061 SH SOLE 2,010,061 Pharmasset Inc. COM 71715N106 30,201 693,319 SH SOLE 693,319 Pozen COM 73941U102 142 21,384 SH SOLE 21,384 Salix Pharmaceuticals, Inc. COM 795435106 26,743 569,485 SH SOLE 569,485 Seattle Genetics Inc. COM 812578102 261,373 17,483,142 SH SOLE 17,483,142 Sucampo CLASS A 864909106 247 64,387 SH SOLE 64,387 Threshold Pharma COM 885807107 4,151 3,075,389 SH SOLE 3,075,389 Trimeris Inc. COM 896263100 8,549 3,475,475 SH SOLE 3,475,475 Via Pharmaceuticals COM 92554T103 4 102,881 SH SOLE 102,881 Viropharma Inc. COM 928241108 181,203 10,462,071 SH SOLE 10,462,071 Xenoport COM 98411C100 6,816 800,000 SH SOLE 800,000 YM Biosciences COM 984238105 21,206 9,101,282 SH SOLE 9,101,282 Ziopharm Oncology Inc. COM 98973P101 4,870 1,045,000 SH SOLE 1,045,000 Alere Inc. Conv. Notes 3% 5/15/16 CONV BONDS 01449JAA3 3,706 3,500,000 PRN SOLE 3,500,000 Amylin Pharmaceuticals Notes 2.5% 4/15/11 CONV BONDS 032346AD0 6,248 6,250,000 PRN SOLE 6,250,000 Biomarin Pharmaceuticals Notes 1.875% 4/23/2017 CONV BONDS 09061GAD3 5,679 3,910,000 PRN SOLE 3,910,000 Human Genome 2.25% 10/15/11 CONV BONDS 444903AK4 7,183 4,500,000 PRN SOLE 4,500,000 Incyte Genomics Notes 4.75% 10/1/2015 CONV BONDS 45337CAH5 331,300 160,000,000 PRN SOLE 160,000,000 Intermune Inc Notes .25% 3/01/2011 CONV BONDS 45884XAC7 49,337 29,313,000 PRN SOLE 29,313,000 Intermune Inc Notes 5% 3/1/15 CONV BONDS 45884XAD5 43,851 20,900,000 PRN SOLE 20,900,000 Salix 144A 5.5% 8/15/28 CONV BONDS 795435AB2 228,730 44,500,000 PRN SOLE 44,500,000 Salix 2.75% 5/15/15 CONV BONDS 795435AC0 166,260 130,400,000 PRN SOLE 130,400,000
-----END PRIVACY-ENHANCED MESSAGE-----